ECGI Holdings (OTC: ECGI), a diversified holding company with a unique portfolio in viticulture, hospitality and luxury fashion, is reporting on the success of its Allon equestrian apparel line during the American Equestrian Trade Association (“AETA”) International trade show, which was held in Dallas. According to the company, the launch, which included a range of show coats, show shirts, breeches, safety vest covers and jewelry, “drew significant attention from key retailers.” The company called the trade show a “pivotal moment” for Allon, noting that the line continues to gain momentum in the highly competitive equestrian market.

“The positive feedback we received, especially for our safety vest cover, reinforces our belief in the Allon brand,” said ECGI Holdings CEO Jamie Steigerwald in the press release. “We are excited about the future and the role Allon will play in elevating the equestrian apparel industry.”

To view the full press release, visit https://ibn.fm/zzr3W

About ECGI Holdings Inc.

ECGI Holdings is a diversified holding company with a distinctive portfolio that spans the global $350 billion luxury brands market. The company’s focus areas include viticulture, luxury fashion and the equestrian markets, which collectively represent significant growth opportunities. In viticulture, ECGI owns and manages Vintner’s Caldera Ranch, a five-acre vineyard in Lake County, California, specializing in Petite Sirah. This bold and rich wine caters to the $252 billion global luxury-wine market’s growing demand for unique, high-quality experiences. Additionally, Vintner’s Caldera Ranch serves as an exclusive short-term rental, tapping into the $121 billion short-term rental market, and offering a unique and immersive wine experience for discerning enthusiasts. In the fashion and equestrian sectors, ECGI has strategically invested in Pacific Saddlery, a premier manufacturer and retailer in the $6.5 billion equestrian-apparel market and the $11 billion equestrian-equipment market. The integration of luxury fashion with equestrian needs underscores the company’s commitment to delivering sophistication and innovation. This unique blend of investments in wine, fashion and equestrian markets highlights ECGI Holdings’ dedication to positioning itself as a distinctive player at the intersection of viticulture and luxury lifestyle. For more information about the company, please visit www.ECGIHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to ECGI are available in the company’s newsroom at https://ibn.fm/ECGINOTE TO INVESTORS: The latest news and updates relating to ECGI are available in the company’s newsroom at https://ibn.fm/ECGI

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

McEwen Mining (NYSE: MUX) (TSX: MUX), a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina, has closed on the acquisition of the Timberline Resources Corporation (TSX.V: TBR) (OTCQB: TLRS). The transaction, which was overwhelmingly approved by Timberline shareholders during an Aug. 16, 2024, special meeting, involved the acquisition of all issued and outstanding common shares of Timberline through a merger between Timberline and a wholly owned subsidiary of McEwen Mining.

“We are pleased to bring Timberline’s assets into McEwen Mining and offer a warm welcome to its shareowners,” said McEwen Mining chair and chief owner Rob McEwen in the press release. “We aim to move the Eureka project forward on multiple fronts, including additional exploration drilling, permitting activities and development planning. Nevada is a place where we want to operate for a long time; our priority is adding opportunities for growth at a reasonable cost.”

To view the full press release, visit https://ibn.fm/xLAbY

About McEwen Mining Inc.

McEwen Mining is a gold and silver producer with operations in Nevada, Canada, Mexico and Argentina. The company also owns approximately 48% of McEwen Copper, which owns the large, advanced-stage Los Azules copper project in Argentina. The company’s objective is to improve the productivity and life of its assets with the goal of increasing the share price and providing an investor yield. Rob McEwen, chair and chief owner, has a personal investment in the companies of $225 million. His annual salary is $1. To learn more about the company, visit www.McEwenMining.com.

NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/MUX

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Renforth Resources (CSE: RFR) (OTCQB: RFHRF) (FSE: 9RR) today updated shareholders on the completed summer exploration activities and those set to begin on its wholly owned Malartic Metals Package (“MMP”) property and its wholly owned Parbec gold deposit, both located in Malartic, Quebec. According to the update, work at the MMP property has identified the Victoria polymetallic system, extending from the surface to a drilled depth of approximately 200m, and led to the discovery of the Beaupré copper/silver zone, containing chalcopyrite, bornite and silver on the surface over approximately 175m in length. In addition, Renforth has completed an initial soil sampling program at Parbec to test previously unexplored areas to potentially identify near-surface gold within the Pontiac.

“Our team continues to develop our understanding of our Beaupré copper discovery, testing its size on surface under cover and we have commenced testing mineralized material from our Victoria polymetallic system for suitability for pre-concentration in a processing flow sheet, funded by the Government of Quebec. We are also once again working on our Parbec gold deposit, testing our new understanding of the structure and identifying a location to strip the overburden in order to commence bulk/metallurgical test work. Our team is delivering on multiple fronts with success in the field, laying the groundwork for our winter exploration season,” said Nicole Brewster, Renforth CEO.

To view the full press release, visit https://ibn.fm/xmZyv

About Renforth Resources Inc.

Renforth is a battery metals area play with the dominant brownfield land position south of the world class Cadillac-Larder Lake Fault (“CLLF”) in the prolific Cadillac and Malartic mining camps of Quebec’s Abitibi. Offering exposure to gold, zinc, nickel, copper, cobalt and more, including lithium, Renforth’s land position encompasses several areas of interest. Renforth’s position is unique in that both the battery metals mineralization within the Malartic Metals Package (“MMP”) and its gold deposit at Parbec are road accessible, with hydro power crossing the property, in an established and secure mining jurisdiction which regularly ranks as Top 10 (as determined by the Fraser Institute) in the world. Renforth is engaged in the active exploration of the proven MMP battery metals mineralization, working towards a maiden resource statement, and the remodeling of its Parbec gold deposit to incorporate the ~15,000m drilled subsequent to the 2019 effective date of the last MRE. For more information about Renforth, visit www.renforthresources.com.

NOTE TO INVESTORS: The latest news and updates relating to RFHRF are available in the company’s newsroom at https://ibn.fm/RFHRF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that recent data from preclinical studies confirms INM-901, a proprietary small molecule drug candidate, as an oral formulation that will be utilized in the company’s development programs for Alzheimer’s disease. The data shows that the INM-901 formulation can be administered orally and maintains similar drug exposure and therapeutic levels as intraperitoneal (“IP”) delivery over a 24-hour period in the brain. The announcement noted that the oral delivery method offers potential advantages such as lower treatment delivery costs.

“We are excited by the recent data confirming that INM-901 can be delivered across the blood brain barrier to the brain tissue as an oral formulation which provides significant advantages for further development of this compound in the treatment of Alzheimer’s. Similar drug levels in the target tissue are not usually seen between oral versus IP delivery. The supporting data generated by the oral formulation provides an attractive therapeutic approach given the many challenges associated with delivery of drug(s) to the brain,” said Michael Woudenberg, InMed’s Chief Operating Officer and SVP of Chemistry, Manufacturing and Controls (“CMC”).

To view the full press release, visit https://ibn.fm/MxWaC

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. Together with its subsidiary, BayMedica, InMed has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. It is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, has entered into a $2 million Investment Commitment Agreement with RK Stone Miami LLC, an affiliate of the largest shareholder of the company, Mr. Daniel Stone. Under the terms of the agreement, Scinai may issue and sell ASDs to the investor, from time to time through December 31, 2024, for an aggregate purchase price of up to $2 million. The agreement does not require the company to register for resale the ADSs to be issued under the agreement.

To view the full press release, visit https://ibn.fm/k28ce

About Scinai Immunotherapeutics Ltd.

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and preclinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN